A Phase 1/2 interventional study of 6R-MTHF (arfolitixorin) 200 mg/m2 and Levoleucovorin 200 mg/m2 in Colonic Neoplasms, sponsored by Isofol Medical AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by Isofol Medical AB · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Colonic Neoplasms with a site in Sweden — 7 open to participants now, 12 under way, 2 of them phase 3. Colonic Neoplasms · Sweden.
Among the 35 studies in Colonic Neoplasms with a site in Sweden, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 1/2, and was the 13th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
Browse Colonic Neoplasms studies →7 of the 35 studies in Colonic Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Sweden, United States, Canada and 6 more countries
Ages 18+
GlaxoSmithKline · Sites in Sweden, United States, Argentina and 25 more countries
Ages 18+
Ann-Sofie Backman · Sites in Sweden, Denmark
Ages 30+
University Hospital, Linkoeping · Sites in Sweden
Ages 18+
Göteborg University · Sites in Sweden
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 11 · Phase 4 2
First in 1998; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 245 across the 24 interventional studies, 1,100 across the 10 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 35 have an industry lead sponsor. The 10 most frequent:
Isofol Medical AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Isofol Medical AB has 2 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Colonic Neoplasms with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT04701853Göteborg UniversitySpecific Training After Stoma Surgery | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Colonic Neoplasms with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and Levoleucovorin (Isovorin®), respectively (60 and 200 mg/m2).
The purpose of this study is to compare the concentration of [6R] 5,10-methylene-THF, 5-formyl-THF, 5-methyl-THF and THF in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different does of Modufolin® and Levoleucovorin (Isovorin®), respectively (60 and 200 mg/m2).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One i.v. bolus injection of study drug after the patient has been anaesthetized.
Drug: Levoleucovorin 200 mg/m2
One i.v. bolus injection of study drug after the patient has been anaesthetized.
Drug: Levoleucovorin 60 mg/m2
One i.v. bolus injection of study drug after the patient has been anaesthetized.
Drug: 6R-MTHF (arfolitixorin) 200 mg/m2
One i.v. bolus injection of study drug after the patient has been anaesthetized.
Drug: 6R-MTHF (arfolitixorin) 60 mg/m2
Drug page: L-(+)-methylenetetrahydrofolic acid
i.v. bolus injection
Also known as: Modufolin®, ISO-901, [6R] 5,10-methylenetetrahydrofolate, arfolitixorin
Drug page: Levoleucovorin
i.v. bolus injection
Also known as: Isovorin®
Drug page: L-(+)-methylenetetrahydrofolic acid
i.v. bolus injection
Also known as: Modufolin®, ISO-901, [6R] 5,10-methylenetetrahydrofolate, arfolitixorin
Drug page: Levoleucovorin
i.v. bolus injection
Also known as: Isovorin®
Concentration of [6R]-5,10-methylene-THF in Tumor Tissue
Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in tumor tissue after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue
Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in mucosa adjacent to the tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6S]-5-THF in Tumor Tissue
Comparison of concentration of the metabolite \[6S\]-5-THF in tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6S]-5-THF in Adjacent Mucosa Tissue
Comparison of concentration of the metabolite \[6S\]-5-THF in mucosa adjacent to the tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6S]-5-methyl-THF in Tumor Tissue
Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue
Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in mucosa adjacent to the tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6S]-5-formyl-THF in Tumor Tissue
Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue
Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in mucosa adjacent to the tumor after the different treatments.
Time frame: Sample taken Day 1 (Day of surgery) at 0 min (before anesthetics) and 5, 10, 20, 40, 60, 90, 120, 180, 240, 360 min after study drug administration, and 24 h after study drug administration
AUC(0-2h) of [6R]-5,10-methylene-THF
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF
Time frame: Samples taken Day 1 (Day of surgery)
AUC(0-2h) of [6S]-5-THF
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-THF
Time frame: Samples taken Day 1 (Day of surgery)
AUC(0-2h) of [6S]-5-methyl-THF
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite: \[6S\]-5-methyl-THF
Time frame: Samples taken Day 1 (Day of surgery)
AUC(0-2h) of [6SR]-5-formyl-THF
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-formyl-THF
Time frame: Samples taken Day 1 (Day of surgery)
AUC(Last) of [6R]-5,10-methylene-THF
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
AUC(Last) of [6S]-5-THF
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
AUC(Last) of [6S]-5-methyl-THF
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-methyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
AUC(Last) of [6S]-5-formyl-THF
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-formyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Cmax of [6R]-5,10-methylene-THF
Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\]-5,10-methylene-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Cmax of [6S]-5-THF in Plasma
Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Cmax of [6S]-5-methyl-THF in Plasma
Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-methyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Cmax of [6S]-5-formyl-THF in Plasma
Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\] 5,10- methylene-THF and the metabolites: \[6S\]-5-THF, \[6S\]-5-methyl-THF, and \[6S\]-5-formyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Tmax of [6R]-5,10-methylene-THF
Timepoint (tmax) when Cmax in plasma occurs of the active substance in Modufolin: \[6R\]-5,10-methylene-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Tmax of [6S]-5-THF
Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Tmax of [6S]-5-methyl-THF
Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-methyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Tmax of [6S]-5-formyl-THF
Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-formyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(1/2) of [6R]-5,10-methylene-THF
Terminal plasma elimination half-life time for the active substance in Modufolin: \[6R\]-5,10-methylene-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(1/2) of [6S]-5-THF
Terminal plasma elimination half-life time for the metabolite \[6S\]-5-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(1/2) of [6S]-5-methyl-THF
Terminal plasma elimination half-life time for the metabolite \[6S\]-5-methyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(1/2) of [6S]-5-formyl-THF
Terminal plasma elimination half-life time for the metabolite \[6S\]-5-formyl-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(Last) of [6R]-5,10-methylene-THF
The time-point for the last measurable concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(Last) of [6S]-5-THF
The time-point for the last measurable concentration for the metabolite \[6S\]-5-TH in plasma
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(Last) of [6S]-5-methyl-THF
The time-point for the last measurable concentration for the metabolite \[6S\]-5-methyl-THF in plasma
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
T(Last) of [6S]-5-formyl-THF
The time-point for the last measurable concentration for the metabolite \[6S\]-5-formyl-THF in plasma
Time frame: Samples taken Day 1 (Day of surgery) and Day 2
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6R]-5,10-methylene-THF
Correlation between the exposure of \[6R\]-5,10-methylene-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6R\]-5,10-methylene-THF in the tumor or adjacent mucosa at surgery.
Time frame: Samples taken Day 1 (Day of surgery)
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-THF
Correlation between the exposure of \[6S\]-5-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-THF in the tumor or adjacent mucosa at surgery.
Time frame: Samples taken Day 1 (Day of surgery)
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-methyl-THF
Correlation between the exposure of \[6S\]-5-methyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-methyl-THF in the tumor or adjacent mucosa at surgery.
Time frame: Samples taken Day 1 (Day of surgery)
Correlation Between Plasma and Tissue Concentration (Tumor and Mucosa) for [6S]-5-formyl-THF
Correlation between the exposure of \[6S\]-5-formyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-formyl-THF in the tumor or adjacent mucosa at surgery.
Time frame: Samples taken Day 1 (Day of surgery)
Gene Expression Ratios (Mucosa:Tumor)
Concentration of different genes involved in folate transport and metabolism were analysed in both tumor and adjacent mucosa. The concentration in mucosa was divided by the concentration in tumor. A value above 1 indicate that the gene expression was higher in mucosa than in tumor and a value below 1 that the gene expression was higher in tumor than in mucosa.
Time frame: Sample taken Day 1 (Day of Surgery)
Correlation of Gene Expression in Tumor and Adjacent Mucosa
Concentration of the gene expression was analysed in both tumor and adjacent mucosa. The presence of any correlation between the results (i.e., concentration of the gene expression in tumor versus adjacent mucosa) was evaluated for each treatment. No evaluation was done between treatments.
Time frame: Sample taken Day 1 (Day of Surgery)
Homocystein Concentration
Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2, and Day 5 (End of study visit).
Time frame: Samples taken at Screening visit, Day 2, and End of Study (Day 5)
S-Folate Concentration
Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit).
Time frame: Samples taken at Screening visit, Day 2 and End of Study (Day 5)
Change in Homocystein Concentration From Screening
Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted. The criteria for assessment categories "normal", "low" and "high" were based on the reference ranges for plasma-Homocystein as follows: "low" \<4,7 mcmol/L; "normal" =\> 4,7 and \<=16 mcmol/L; "high" \>16 mcmol/L. Values were applicable for both male and female adults.
Time frame: Samples taken at Screening visit, Day 2 and End of Study (Day 5)
Change in S-Folate Concentration From Screening
Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted.
Time frame: Samples taken at Screening visit, Day 2 and End of Study (Day 5)
Number of AEs Per Severity
Number of reported AEs per treatment with respect to severity
Time frame: Screening visit until end of study, Day 5
| Milestone | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | 6R-MTHF 200 mg/m2 | 6R-MTHF 60 mg/m2 |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 |
| Completed | 8 | 7 | 8 | 8 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in tumor tissue after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6R]-5,10-methylene-THF in Tumor Tissue | 1871 ± 1159 | 959 ± 417 | 4725 ± 2210 | 2393 ± 1920 |
Comparison of concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF in mucosa adjacent to the tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6R]-5,10-methylene-THF in Adjacent Mucosa Tissue | 1333 ± 852 | 626 ± 439 | 5099 ± 3927 | 3481 ± 3926 |
Comparison of concentration of the metabolite \[6S\]-5-THF in tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6S]-5-THF in Tumor Tissue | 1329 ± 720 | 933 ± 598 | 4175 ± 3127 | 2219 ± 1995 |
Comparison of concentration of the metabolite \[6S\]-5-THF in mucosa adjacent to the tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6S]-5-THF in Adjacent Mucosa Tissue | 1333 ± 852 | 626 ± 439 | 5099 ± 3927 | 3481 ± 3926 |
Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6S]-5-methyl-THF in Tumor Tissue | 3574 ± 2415 | 1904 ± 918 | 4396 ± 1858 | 1882 ± 1204 |
Comparison of concentration of the metabolite \[6S\]-5-methyl-THF in mucosa adjacent to the tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6S]-5-methyl-THF in Adjacent Mucosa Tissue | 3667 ± 2043 | 1216 ± 455 | 2494 ± 765 | 2066 ± 1517 |
Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6S]-5-formyl-THF in Tumor Tissue | 3611 ± 3899 | 512 ± 259 | 100 ± 47 | 57 ± 48 |
Comparison of concentration of the metabolite \[6S\]-5-formyl-THF in mucosa adjacent to the tumor after the different treatments.
| pmol/g | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration of [6S]-5-formyl-THF in Adjacent Mucosa Tissue | 5456 ± 3963 | 1403 ± 640 | 82 ± 77 | 42 ± 18 |
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(0-2h) of [6R]-5,10-methylene-THF | 326.40261 ± 61.98416 | 239.90076 ± 0 | 7734.09113 ± 1557.76552 | 0 ± 0 |
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(0-2h) of [6S]-5-THF | 827.1083 ± 178.23243 | 640.0489 ± 0 | 19408.1712 ± 3000.64794 | 5639.2700 ± 885.82223 |
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite: \[6S\]-5-methyl-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(0-2h) of [6S]-5-methyl-THF | 2336.24432 ± 829.18634 | 1258.60184 ± 247.51353 | 2277.89290 ± 1132.95603 | 997.74091 ± 413.68052 |
Area under the plasma concentration versus time curve from time 0 to 2 hours, for the metabolite \[6S\]-5-formyl-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(0-2h) of [6SR]-5-formyl-THF | 29911.9184 ± 6924.78031 | 7595.4599 ± 764.27650 | 0 ± 0 | 0 ± 0 |
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the active substance in Modufolin: \[6R\]-5,10-methylene-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(Last) of [6R]-5,10-methylene-THF | 462.10746 ± 221.85761 | 239.90076 ± 0 | 7910.61038 ± 1623.24300 | 2272.78010 ± 448.01407 |
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(Last) of [6S]-5-THF | 2231.1443 ± 1051.06650 | 640.0489 ± 0 | 28466.5389 ± 5303.28705 | 6766.9104 ± 1484.91243 |
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-methyl-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(Last) of [6S]-5-methyl-THF | 32206.2771 ± 9121.1818 | 7689.0921 ± 5164.6098 | 21737.2428 ± 21757.1545 | 5495.1924 ± 6110.0065 |
Area under the plasma concentration versus time curve, from time 0 to the last time point, for the metabolite \[6S\]-5-formyl-THF
| mcg*h/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| AUC(Last) of [6S]-5-formyl-THF | 43429.1885 ± 12411.2844 | 9637.0308 ± 1637.2118 | 75.6174 ± 69.2176 | 50.1858 ± 0 |
Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\]-5,10-methylene-THF
| µg/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Cmax of [6R]-5,10-methylene-THF | 195.0000 ± 40.76763 | 123.0000 ± 0 | 22087.5000 ± 5635.45853 | 6452.8571 ± 559.18477 |
Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-THF
| µg/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Cmax of [6S]-5-THF in Plasma | 577.6250 ± 190.74436 | 335.0000 ± 0 | 13372.5000 ± 2108.15932 | 5015.7143 ± 427.35064 |
Maximum concentration (Cmax) in plasma of the metabolite \[6S\]-5-methyl-THF
| µg/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Cmax of [6S]-5-methyl-THF in Plasma | 2786.25000 ± 822.6253 | 1078.00000 ± 275.26206 | 2020.50000 ± 1142.25116 | 800.42857 ± 396.41849 |
Maximum concentration (Cmax) in plasma of the active substance in Modufolin: \[6R\] 5,10- methylene-THF and the metabolites: \[6S\]-5-THF, \[6S\]-5-methyl-THF, and \[6S\]-5-formyl-THF
| µg/L | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Cmax of [6S]-5-formyl-THF in Plasma | 32962.5000 ± 8594.17369 | 10168.3333 ± 2271.47896 | 252.7500 ± 141.51178 | 261.0000 ± 0 |
Timepoint (tmax) when Cmax in plasma occurs of the active substance in Modufolin: \[6R\]-5,10-methylene-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Tmax of [6R]-5,10-methylene-THF | 1.14285857 ± 0.53079605 | 1.00000000 ± 0 | 0.08333000 ± 0.00000000 | 0.08333000 ± 0.00000000 |
Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Tmax of [6S]-5-THF | 2.02083375 ± 1.03677360 | 1.50000000 ± 0 | 0.38541750 ± 0.24775936 | 0.09523571 ± 0.03149956 |
Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-methyl-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Tmax of [6S]-5-methyl-THF | 4.75000000 ± 1.38873015 | 2.41666667 ± 0.66458007 | 3.75000000 ± 1.16496475 | 2.92857143 ± 0.93222724 |
Timepoint (tmax) when Cmax in plasma occurs for the metabolite \[6S\]-5-formyl-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| Tmax of [6S]-5-formyl-THF | 0.12499750 ± 0.08908753 | 0.08333000 ± 0.00000000 | 0.10416500 ± 0.04167000 | 0.08333000 ± 0 |
Terminal plasma elimination half-life time for the active substance in Modufolin: \[6R\]-5,10-methylene-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(1/2) of [6R]-5,10-methylene-THF | 3.07069184 ± 2.48958159 | 9.12204918 ± 0 | 0.90893994 ± 0.62586420 | 0.34368840 ± 0.06725217 |
Terminal plasma elimination half-life time for the metabolite \[6S\]-5-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(1/2) of [6S]-5-THF | 5.59459251 ± 1.76982092 | 0 ± 0 | 1.24808943 ± 0.23995973 | 0.96378070 ± 0.19174152 |
Terminal plasma elimination half-life time for the metabolite \[6S\]-5-methyl-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(1/2) of [6S]-5-methyl-THF | 7.0955575 ± 1.18981597 | 10.7281060 ± 8.80812064 | 9.0743346 ± 3.84317226 | 8.5121573 ± 2.80644764 |
Terminal plasma elimination half-life time for the metabolite \[6S\]-5-formyl-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(1/2) of [6S]-5-formyl-THF | 1.51328500 ± 0.34108131 | 0.98944069 ± 0.20217367 | 0.23180085 ± 0.13438901 | 0 ± 0 |
The time-point for the last measurable concentration of the active substance in Modufolin: \[6R\]-5,10-methylene-THF
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(Last) of [6R]-5,10-methylene-THF | 3.00000000 ± 1.41421356 | 2.00000000 ± 0 | 3.25000000 ± 1.38873015 | 1.35714286 ± 0.24397502 |
The time-point for the last measurable concentration for the metabolite \[6S\]-5-TH in plasma
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(Last) of [6S]-5-THF | 4.75000000 ± 1.48804762 | 2.00000000 ± 0 | 5.75000000 ± 0.70710678 | 3.42857143 ± 0.78679579 |
The time-point for the last measurable concentration for the metabolite \[6S\]-5-methyl-THF in plasma
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(Last) of [6S]-5-methyl-THF | 24.0000000 ± 0.00000000 | 12.0000000 ± 9.29516003 | 15.0000000 ± 9.62140471 | 8.5714286 ± 6.80336051 |
The time-point for the last measurable concentration for the metabolite \[6S\]-5-formyl-THF in plasma
| h | L-LV(200) | L-LV(60) | Mod(200) | Mod(60) |
|---|---|---|---|---|
| T(Last) of [6S]-5-formyl-THF | 6.00000000 ± 0.00000000 | 8.33333333 ± 7.73735528 | 0.33333500 ± 0.23570226 | 0.16667000 ± 0 |
Correlation between the exposure of \[6R\]-5,10-methylene-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6R\]-5,10-methylene-THF in the tumor or adjacent mucosa at surgery.
| correlation coefficient | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| AUC(0-2h) vs. conc in tumor | 0.54039 | NA | -0.21666 | — |
| AUC(0-2h) vs. conc in adjacent mucosa | 0.68223 | NA | 0.27618 | — |
Correlation between the exposure of \[6S\]-5-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-THF in the tumor or adjacent mucosa at surgery.
| correlation coefficient | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| AUC(0-2h) vs. conc in tumor | -0.02188 | NA | 0.27018 | 0.38298 |
| AUC(0-2h) vs. conc in adjacent mucosa | 0.07937 | NA | 0.34905 | 0.45404 |
Correlation between the exposure of \[6S\]-5-methyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-methyl-THF in the tumor or adjacent mucosa at surgery.
| correlation coefficient | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| AUC(0-2h) vs. conc in tumor | 0.73743 | 0.44757 | 0.03292 | 0.09033 |
| AUC(0-2h) vs. conc in adjacent mucosa | 0.76502 | 0.34496 | -0.66295 | 0.36854 |
Correlation between the exposure of \[6S\]-5-formyl-THF following 2 hours after dosing (AUC\[0-2h\]) and the concentration of \[6S\]-5-formyl-THF in the tumor or adjacent mucosa at surgery.
| correlation coefficient | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| AUC(0-2h) vs. conc in tumor | 0.68778 | 0.11512 | — | — |
| AUC(0-2h) vs. conc in adjacent mucosa | 0.23512 | 0.02576 | — | — |
Concentration of different genes involved in folate transport and metabolism were analysed in both tumor and adjacent mucosa. The concentration in mucosa was divided by the concentration in tumor. A value above 1 indicate that the gene expression was higher in mucosa than in tumor and a value below 1 that the gene expression was higher in tumor than in mucosa.
| Ratio | Modufolin 60 mg/m2 | Modufolin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Levoleucovorin 200 mg/m2 |
|---|---|---|---|---|
| AMT | 1.35 | 5.60 | 1.86 | 3.33 |
| PCFT | 2.03 | 2.75 | 2.92 | 2.45 |
| FPGS | 0.47 | 0.70 | 0.63 | 0.83 |
| MTHFS | 0.51 | 0.87 | 0.83 | 0.72 |
| ABCC3 | 1.83 | 3.37 | 2.48 | 4.15 |
| GGH | 0.50 | 0.47 | 0.35 | 0.31 |
| ABCC1 | 0.41 | 0.55 | 0.77 | 0.43 |
| MTHFD1L | 0.15 | 0.24 | 0.29 | 0.35 |
| SHMT1 | 0.89 | 1.13 | 0.72 | 2.26 |
| SHMT2 | 0.31 | 0.34 | 0.38 | 0.48 |
| RFC-1 | 0.48 | 0.66 | 0.53 | 1.18 |
Concentration of the gene expression was analysed in both tumor and adjacent mucosa. The presence of any correlation between the results (i.e., concentration of the gene expression in tumor versus adjacent mucosa) was evaluated for each treatment. No evaluation was done between treatments.
| Normalized concentration | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| AMT | -0.47193 | -0.70730 | 0.75404 | 0.42972 |
| PCFT | 0.11497 | 0.89976 | 0.58502 | 0.88128 |
| FPGS | 0.17664 | -0.64743 | 0.88682 | 0.97624 |
| MTHFS | 0.95840 | 0.58419 | 0.43194 | 0.94364 |
| ABCC3 | 0.00322 | 0.77700 | -0.25891 | -0.38987 |
| GGH | 0.78928 | -0.09737 | 0.46883 | 0.93711 |
| ABCC1 | 0.74757 | 0.14436 | -0.16724 | 0.82963 |
| MTHFD1L | 0.74459 | 0.20955 | 0.37160 | 0.32113 |
| SHMT1 | 0.59183 | 0.05531 | 0.67853 | 0.50966 |
| SHMT2 | 0.55508 | -0.71666 | 0.86266 | 0.81040 |
| RFC-1 | 0.64565 | -0.02450 | 0.23312 | 0.31800 |
Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2, and Day 5 (End of study visit).
| μmol/L | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration at Screening | 12.59 ± 4.28 | 11.27 ± 3.98 | 14.53 ± 6.22 | 13.80 ± 3.83 |
| Concentration at Day 2 | 6.41 ± 2.32 | 6.40 ± 3.10 | 7.06 ± 1.97 | 8.14 ± 2.63 |
| Concentration at Day 5 | 9.04 ± 2.53 | 9.18 ± 4.65 | 10.20 ± 3.34 | 10.10 ± 2.64 |
Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit).
| nmol/L | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 |
|---|---|---|---|---|
| Concentration at Screening | 21.75 ± 8.88 | 21.00 ± 6.54 | 15.03 ± 5.20 | 18.71 ± 7.65 |
| Concentration at Day 2 | 45.00 ± 0.00 | 45.00 ± 0.00 | 45.00 ± 0.00 | 45.00 ± 0.00 |
| Concentration at Day 5 | 44.75 ± 0.71 | 40.80 ± 9.39 | 44.14 ± 2.27 | 40.29 ± 3.73 |
Blood samples for folate biomarker (homocystein) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted. The criteria for assessment categories "normal", "low" and "high" were based on the reference ranges for plasma-Homocystein as follows: "low" \<4,7 mcmol/L; "normal" =\> 4,7 and \<=16 mcmol/L; "high" \>16 mcmol/L. Values were applicable for both male and female adults.
| Participants | Modufolin 60 mg/m2 | Modufolin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Levoleucovorin 200 mg/m2 |
|---|---|---|---|---|
| Normal at Screen and Normal at Day 2 | 5 | 4 | 4 | 4 |
| Shift from Normal at Screen to Low at Day 2 | 0 | 1 | 2 | 2 |
| Shift from High at Screen to Normal at Day 2 | 2 | 3 | 0 | 2 |
| Normal at Screen and Normal at Day 5 | 5 | 5 | 4 | 6 |
| Shift from Normal at Screen to Low at Day 5 | 0 | 0 | 1 | 0 |
| Shift from High at Screen and Normal at Day 5 | 2 | 3 | 0 | 2 |
| Missing data Screen to Day 5 | 0 | 0 | 1 | 0 |
Blood samples for folate biomarker (S-folate) analysis were collected at Screening, Day 2 and Day 5 (End of study visit). Changes from screening to later visits were counted.
| Participants | Modufolin 60 mg/m2 | Modufolin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Levoleucovorin 200 mg/m2 |
|---|---|---|---|---|
| Shift from Normal at Screen to High at Day 2 | 7 | 8 | 5 | 8 |
| Missing data Screen to Day 2 | 0 | 0 | 1 | 0 |
| Normal at Screening and Normal at Day 5 | 3 | 1 | 1 | 0 |
| Shift from Normal at Screen to High at Day 5 | 4 | 6 | 4 | 8 |
| Missing data Screen to Day 5 | 0 | 1 | 1 | 0 |
Number of reported AEs per treatment with respect to severity
| Events | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin mg/m2 |
|---|---|---|---|---|
| AEs of mild severity | 1 | 0 | 1 | 5 |
| AEs of moderate severity | 3 | 0 | 7 | 2 |
| AEs of severe severity | 0 | 1 | 2 | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levoleucovorin 200 mg/m2 | — | 0/8 (0%) | 4/8 (50%) |
| Levoleucovorin 60 mg/m2 | — | 1/7 (14.3%) | 2/7 (28.6%) |
| 6R-MTHF 200 mg/m2 | — | 2/8 (25%) | 4/8 (50%) |
| 6R-MTHF 60 mg/m2 | — | 2/8 (25%) | 5/8 (62.5%) |
| Event | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | 6R-MTHF 200 mg/m2 | 6R-MTHF 60 mg/m2 |
|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/8 | 0/7 | 0/8 | 1/8 |
| Acute mycardial infarctionCardiac disorders | 0/8 | 0/7 | 0/8 | 1/8 |
| Postoperative wound complicationInjury, poisoning and procedural complications | 0/8 | 0/7 | 1/8 | 0/8 |
| Anastomotic leakInjury, poisoning and procedural complications | 0/8 | 0/7 | 1/8 | 0/8 |
| Event | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | 6R-MTHF 200 mg/m2 | 6R-MTHF 60 mg/m2 |
|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 0/8 | 0/7 | 0/8 | 2/8 |
| Atrial fibrillationCardiac disorders | 2/8 | 0/7 | 2/8 | 0/8 |
| ParalysisNervous system disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/8 | 1/7 | 0/8 | 0/8 |
| PneumoniaInfections and infestations | 0/8 | 0/7 | 1/8 | 1/8 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/8 | 0/7 | 0/8 | 1/8 |
| FlushingVascular disorders | 0/8 | 0/7 | 0/8 | 1/8 |
| HypotensionVascular disorders | 0/8 | 0/7 | 0/8 | 1/8 |
| VomitingGastrointestinal disorders | 0/8 | 0/7 | 1/8 | 1/8 |
| NauseaGastrointestinal disorders | 0/8 | 0/7 | 1/8 | 0/8 |
| Age, Categorical(Participants) | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 3 | 2 | 2 | 7 |
| >=65 years | 8 | 5 | 6 | 6 | 25 |
| Age, Continuous(years) | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 | Total |
|---|---|---|---|---|---|
| Mean | 80.5 ± 9.15 | 66.71 ± 16.89 | 72 ± 15 | 71.75 ± 11.25 | 72.74 ± 13.07 |
| Sex: Female, Male(Participants) | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 3 | 4 | 16 |
| Male | 4 | 3 | 5 | 4 | 16 |
| Region of Enrollment(Participants) | Levoleucovorin 200 mg/m2 | Levoleucovorin 60 mg/m2 | Modufolin 200 mg/m2 | Modufolin 60 mg/m2 | Total |
|---|---|---|---|---|---|
| Sweden | 8 | 8 | 8 | 8 | 32 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid
Isofol Medical AB